Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says

MT Newswires Live07-08

Vertex Pharmaceuticals' (VRTX) planned $10 billion acquisition of Crinetics Pharmaceuticals (CRNX) may prompt investor questions on the timing of the deal with several major clinical trial results already expected in early 2027, UBS Securities said Monday in a note.

UBS said the deal adds two important rare-disease drugs: Palsonify, used to treat acromegaly, a condition caused by excess growth hormone, and atumelnant, now in late-stage testing for congenital adrenal hyperplasia, a disorder that affects hormone production.

Vertex on Monday described the acquisition as a potential blockbuster with expected sales of more than $5 billion.

The near-term focus will stay on rival cystic fibrosis data expected this summer, while Vertex's own 2027 trial results should provide additional catalysts, UBS said.

UBS has a buy rating on Vertex stock with a $545 price target.

Vertex shares fell 1% in Tuesday trading, and Crinetics declined 0.5%.

Price: 524.45, Change: -5.14, Percent Change: -0.97

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment